Form 4 holding
Chief Medical Officer
NEUROCRINE BIOSCIENCES INC
- Security class
- Common Stock
- Shares / value
- 35,640
- Estimated value
- $4,100,115
- Report date
- 14 Feb 2025
- Price
- $115.04
- Ownership
- Direct
Eiry Roberts
Insider Reports History
- Reporting-owner location
- San Dieo, CA
- Latest reporting-owner signature
- /s/ Brianna M. Dorsi, attorney-in-fact
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for Eiry Roberts
Form 4 holding
Chief Medical Officer
NEUROCRINE BIOSCIENCES INC
- Security class
- Restricted Stock Unit
- Shares / value
- 4,483
- Estimated value
- $595,973
- Report date
- 13 Feb 2024
- Price
- $132.94
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Chief Medical Officer
NEUROCRINE BIOSCIENCES INC
- Security class
- Restricted Stock Unit
- Shares / value
- 4,115
- Estimated value
- $480,414
- Report date
- 13 Feb 2025
- Price
- $116.75
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Bausch Health Companies Inc.
- Security class
- Common Shares, No Par Value
- Shares / value
- 45,871
- Estimated value
- $247,703
- Report date
- 22 May 2026
- Price
- $5.40
- Ownership
- Direct
Form 4 holding
Chief Medical Officer
NEUROCRINE BIOSCIENCES INC
- Security class
- Incentive Stock Option
- Shares / value
- 1,265
- Estimated value
- $54,699
- Report date
- 08 Nov 2024
- Price
- $43.24
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
AMICUS THERAPEUTICS, INC.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 27 Apr 2026
- Price
- $14.46
- Ownership
- Direct
Form 4 holding
Chief Medical Officer
NEUROCRINE BIOSCIENCES INC
- Security class
- Stock Option
- Shares / value
- 43,261
- Estimated value
- Report date
- 12 Feb 2025
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
AMICUS THERAPEUTICS, INC.
- Security class
- Stock Options (right to buy)
- Shares / value
- 42,467
- Estimated value
- Report date
- 06 Jun 2024
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Chief Medical Officer
NEUROCRINE BIOSCIENCES INC
- Security class
- Stock Option
- Shares / value
- 22,529
- Estimated value
- Report date
- 13 Feb 2024
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
AMICUS THERAPEUTICS, INC.
- Security class
- Stock Options (right to buy)
- Shares / value
- 0
- Estimated value
- Report date
- 27 Apr 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Insider Reports Filed by Eiry Roberts
4
BHC
Bausch Health Companies Inc.
- Report period
- 22 May 2026
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 26 May 2026, 19:02
- Role
- Director
- Next action
- Open filing details
3
BHC
Bausch Health Companies Inc.
- Report period
- 19 May 2026
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 20 May 2026, 17:16
- Role
- Director
- Next action
- Open filing details
4
FOLD
AMICUS THERAPEUTICS, INC.
- Report period
- 27 Apr 2026
- Transactions
- 6
- Transaction value
- $0
- Accepted by SEC
- 27 Apr 2026, 16:41
- Role
- Director
- Next action
- Open filing details
4
FOLD
AMICUS THERAPEUTICS, INC.
- Report period
- 05 Jun 2025
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 06 Jun 2025, 16:53
- Role
- Director
- Next action
- Open filing details
4
NBIX
NEUROCRINE BIOSCIENCES INC
- Report period
- 12 Feb 2025
- Transactions
- 11
- Transaction value
- -$258,264
- Accepted by SEC
- 14 Feb 2025, 18:42
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
NBIX
NEUROCRINE BIOSCIENCES INC
- Report period
- 08 Feb 2025
- Transactions
- 3
- Transaction value
- -$115,853
- Accepted by SEC
- 12 Feb 2025, 18:52
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
NBIX
NEUROCRINE BIOSCIENCES INC
- Report period
- 31 Jan 2025
- Transactions
- 3
- Transaction value
- -$222,636
- Accepted by SEC
- 04 Feb 2025, 17:54
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
NBIX
NEUROCRINE BIOSCIENCES INC
- Report period
- 17 Dec 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 19 Dec 2024, 16:47
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
NBIX
NEUROCRINE BIOSCIENCES INC
- Report period
- 08 Nov 2024
- Transactions
- 8
- Transaction value
- +$599,873
- Accepted by SEC
- 12 Nov 2024, 17:58
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
FOLD
AMICUS THERAPEUTICS, INC.
- Report period
- 06 Jun 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 07 Jun 2024, 19:52
- Role
- Director
- Next action
- Open filing details
4
NBIX
NEUROCRINE BIOSCIENCES INC
- Report period
- 13 Feb 2024
- Transactions
- 3
- Transaction value
- -$148,122
- Accepted by SEC
- 15 Feb 2024, 17:51
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
NBIX
NEUROCRINE BIOSCIENCES INC
- Report period
- 06 Feb 2024
- Transactions
- 2
- Transaction value
- -$290,968
- Accepted by SEC
- 08 Feb 2024, 19:28
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
NBIX
NEUROCRINE BIOSCIENCES INC
- Report period
- 31 Jan 2024
- Transactions
- 1
- Transaction value
- -$205,132
- Accepted by SEC
- 02 Feb 2024, 19:29
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
NBIX
NEUROCRINE BIOSCIENCES INC
- Report period
- 22 Dec 2023
- Transactions
- 1
- Transaction value
- -$1,267,448
- Accepted by SEC
- 27 Dec 2023, 16:15
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
NBIX
NEUROCRINE BIOSCIENCES INC
- Report period
- 12 Dec 2023
- Transactions
- 6
- Transaction value
- -$1,675,240
- Accepted by SEC
- 14 Dec 2023, 17:22
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
NBIX
NEUROCRINE BIOSCIENCES INC
- Report period
- 07 Dec 2023
- Transactions
- 18
- Transaction value
- -$9,350,350
- Accepted by SEC
- 11 Dec 2023, 18:18
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
NBIX
NEUROCRINE BIOSCIENCES INC
- Report period
- 06 Dec 2023
- Transactions
- 3
- Transaction value
- -$1,007,780
- Accepted by SEC
- 08 Dec 2023, 19:09
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
NBIX
NEUROCRINE BIOSCIENCES INC
- Report period
- 21 Aug 2023
- Transactions
- 1
- Transaction value
- -$343,388
- Accepted by SEC
- 23 Aug 2023, 20:20
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
FOLD
AMICUS THERAPEUTICS, INC.
- Report period
- 08 Jun 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 12 Jun 2023, 17:38
- Role
- Director
- Next action
- Open filing details
4
NBIX
NEUROCRINE BIOSCIENCES INC
- Report period
- 24 Apr 2023
- Transactions
- 1
- Transaction value
- -$1,490,059
- Accepted by SEC
- 26 Apr 2023, 21:22
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
NBIX
NEUROCRINE BIOSCIENCES INC
- Report period
- 13 Feb 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 15 Feb 2023, 18:15
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
NBIX
NEUROCRINE BIOSCIENCES INC
- Report period
- 06 Feb 2023
- Transactions
- 4
- Transaction value
- -$1,697,707
- Accepted by SEC
- 08 Feb 2023, 18:40
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
NBIX
NEUROCRINE BIOSCIENCES INC
- Report period
- 31 Jan 2023
- Transactions
- 1
- Transaction value
- -$160,254
- Accepted by SEC
- 02 Feb 2023, 16:28
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
FOLD
AMICUS THERAPEUTICS, INC.
- Report period
- 09 Jun 2022
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 10 Jun 2022, 16:11
- Role
- Director
- Next action
- Open filing details
4
NBIX
NEUROCRINE BIOSCIENCES INC
- Report period
- 07 Feb 2022
- Transactions
- 3
- Transaction value
- -$299,590
- Accepted by SEC
- 09 Feb 2022, 18:06
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
NBIX
NEUROCRINE BIOSCIENCES INC
- Report period
- 31 Jan 2022
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 02 Feb 2022, 18:52
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
NBIX
NEUROCRINE BIOSCIENCES INC
- Report period
- 10 Jan 2022
- Transactions
- 1
- Transaction value
- -$196,088
- Accepted by SEC
- 12 Jan 2022, 16:53
- Role
- Chief Medical Officer
- Next action
- Open filing details
4
FOLD
AMICUS THERAPEUTICS, INC.
- Report period
- 10 Jun 2021
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 14 Jun 2021, 19:04
- Role
- Director
- Next action
- Open filing details
3
FOLD
AMICUS THERAPEUTICS, INC.
- Report period
- 10 Jun 2021
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 14 Jun 2021, 19:00
- Role
- Director
- Next action
- Open filing details
4/A
NBIX
NEUROCRINE BIOSCIENCES INC
- Report period
- 12 Nov 2020
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 26 Apr 2023, 21:19
- Role
- Chief Medical Officer
- Next action
- Open filing details